In EGFR-mutated NSCLC, we observed longer TOT with osimertinib compared with pemetrexed with no difference in posttreatment OS, mirroring results of the phase 3 AURA3 trial that demonstrated longer PFS in osimertinib-treated patients versus platinum/pemetrexed-treated patients, but no meaningful prolongation of OS (38, 39). Here, EGFR is linked to non-small cell lung carcinoma.